Oncolytics Biotech Stock Forecast, Price & News

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oncolytics Biotech stock.
View analyst ratings for Oncolytics Biotech or view top-rated stocks.

Wall Street analysts have given Oncolytics Biotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oncolytics Biotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Oncolytics Biotech is scheduled to release its next quarterly earnings announcement on Friday, May 14th 2021.
View our earnings forecast for Oncolytics Biotech.

Oncolytics Biotech Inc. (TSE:ONC) released its quarterly earnings data on Friday, March, 5th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.05.
View Oncolytics Biotech's earnings history.

Oncolytics Biotech's stock was trading at C$2.37 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ONC stock has increased by 57.0% and is now trading at C$3.72.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 12-month price objectives for Oncolytics Biotech's stock. Their forecasts range from C$6.00 to C$6.00. On average, they anticipate Oncolytics Biotech's stock price to reach C$6.00 in the next year. This suggests a possible upside of 61.3% from the stock's current price.
View analysts' price targets for Oncolytics Biotech or view top-rated stocks among Wall Street analysts.

Some companies that are related to Oncolytics Biotech include iTeos Therapeutics (ITOS), Finch Therapeutics Group (FNCH), Achilles Therapeutics plc American Depositary Shares (ACHL), Biotest Aktiengesellschaft (BIO), Aptose Biosciences (APS), Burcon NutraScience (BU), Sigilon Therapeutics (SGTX), Ergomed (ERGO), Inventiva (IVA), 22nd Century Group (XXII), Silence Therapeutics (SLN), Gemini Therapeutics (GMTX), Landos Biopharma (LABP), Terns Pharmaceuticals (TERN) and BELLUS Health (BLU).
View all of ONC's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), (ONCYF) (ONCYF), Resverlogix (RVX), Ballard Power Systems (BLDP), (ECA), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Birchcliff Energy (BIR), Enbridge (ENB) and First Majestic Silver (FR).

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

Shares of ONC and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

One share of ONC stock can currently be purchased for approximately C$3.72.

Oncolytics Biotech has a market capitalization of C$196.30 million.

The official website for Oncolytics Biotech is www.oncolyticsbiotech.com.

Oncolytics Biotech is headquartered at 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada.

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.